Skip navigation
7th Annual Clinical Data Disclosure, Transparency & Dissemination promo banner
Patient Registries, Real World Evidence and HEOR promo banner
Medicare Pricing & Contracting Congress promo banner
PAP 2020 – 21st Annual Patient Assistance and Access Programs promo banner

Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen

Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.
Published Date: 
December 7, 2014
URL: 
http://www.biopharminternational.com/biopharm/Biologics/Sandozs-Biosimilar-Shows-Similarity-to-Amgens-Neup/ArticleStandard/Article/detail/862900?contextCategoryId=435&ref=25
Title: 
Sandoz's Biosimilar Shows Similarity to Amgen's Neupogen
Short Description: 
Sandoz announces their version of filgrastim, a follow-on biologic for the treatment of neutropenia, is as safe and effective as Amgen's Neupogen.